Tslverde
2021-06-07
Good. Please like
Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":115773537,"tweetId":"115773537","gmtCreate":1623033041129,"gmtModify":1634096035307,"author":{"id":3556329315079497,"idStr":"3556329315079497","authorId":3556329315079497,"authorIdStr":"3556329315079497","name":"Tslverde","avatar":"https://static.tigerbbs.com/5f52f5991ed363792008cd868f78181c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good. Please like</p></body></html>","htmlText":"<html><head></head><body><p>Good. Please like</p></body></html>","text":"Good. Please like","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/115773537","repostId":1179953695,"repostType":4,"repost":{"id":"1179953695","kind":"news","pubTimestamp":1623032758,"share":"https://www.laohu8.com/m/news/1179953695?lang=&edition=full","pubTime":"2021-06-07 10:25","market":"us","language":"en","title":"Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1179953695","media":"seekingalpha","summary":"Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits F","content":"<ul><li>Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the company with Eisai(OTCPK:ESALF).</li><li>While scientists question the efficacy of aducanumab which had a mixed performance in late-stage trials, the patient advocacy groups continue to stand behind the treatment.</li><li>\"We support a decision for approval of aducanumab ... It ushers in a new era of potential treatments,\" Reuters quoted Dr. Joanne Pike, chief strategy officer at the Alzheimer's Association as saying.</li><li>However, the analysts appear divided on the potential for aducanumab to secure a regulatory nod. Citing management comments over plans for its commercialization, Oppenheimer raised the probability of approval to 50% from 30%.</li><li>Recently, Mizuho analyst Salim Syed estimated Biogen shares could reach ~$400 or ~$200 depending on the FDA decision.</li><li>Meanwhile, Bank of America remains cautious with the analyst Geoff Meacham giving the treatment only a 25% chance of avoiding the FDA rejection.</li><li>A positive decision by the FDA “could signal probably more regulatory flexibility,\" Meacham noted trying to predict the impact of the decision by the regulator which remains under the Acting Commissioner Janet Woodcock.</li><li>Meanwhile, Seeking Alpha contributor Trent Welsh thinks that in the event of a negative outcome, the activist involvement could mitigate the losses for investors as the contributor initiates a very bullish view on Biogen ahead of the FDA action date for aducanumab on June 07. </li></ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 10:25 GMT+8 <a href=https://seekingalpha.com/news/3703521-biogen-surges-ahead-of-key-fda-decision-amid-mixed-views-on-potential-alzheimers-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the...</p>\n\n<a href=\"https://seekingalpha.com/news/3703521-biogen-surges-ahead-of-key-fda-decision-amid-mixed-views-on-potential-alzheimers-therapy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://seekingalpha.com/news/3703521-biogen-surges-ahead-of-key-fda-decision-amid-mixed-views-on-potential-alzheimers-therapy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1179953695","content_text":"Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the company with Eisai(OTCPK:ESALF).While scientists question the efficacy of aducanumab which had a mixed performance in late-stage trials, the patient advocacy groups continue to stand behind the treatment.\"We support a decision for approval of aducanumab ... It ushers in a new era of potential treatments,\" Reuters quoted Dr. Joanne Pike, chief strategy officer at the Alzheimer's Association as saying.However, the analysts appear divided on the potential for aducanumab to secure a regulatory nod. Citing management comments over plans for its commercialization, Oppenheimer raised the probability of approval to 50% from 30%.Recently, Mizuho analyst Salim Syed estimated Biogen shares could reach ~$400 or ~$200 depending on the FDA decision.Meanwhile, Bank of America remains cautious with the analyst Geoff Meacham giving the treatment only a 25% chance of avoiding the FDA rejection.A positive decision by the FDA “could signal probably more regulatory flexibility,\" Meacham noted trying to predict the impact of the decision by the regulator which remains under the Acting Commissioner Janet Woodcock.Meanwhile, Seeking Alpha contributor Trent Welsh thinks that in the event of a negative outcome, the activist involvement could mitigate the losses for investors as the contributor initiates a very bullish view on Biogen ahead of the FDA action date for aducanumab on June 07.","news_type":1},"isVote":1,"tweetType":1,"viewCount":135,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":15,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/115773537"}
精彩评论